

Supplementary literature search and reference record

Manuscript 126695 | Literature search executed 14 September 2026

1 Scope and selection approach

The revision search addressed functional cure of chronic hepatitis B, treatments and safety, serum biomarkers, prediction models, outcomes after HBsAg loss, regional applicability and society guidance. This is a structured narrative review with purposive source selection. The PubMed publication-date range was 1 January 2000 to 14 September 2026. No language or human-study database filter was imposed; English-language availability was considered during selection. The Cochrane review search used no date filter; dates and relevance were checked at record level.

Pivotal randomized comparisons, direct model validations, negative studies, serious harms and current guidance were prioritized for abstract and accessible primary-source appraisal. Selected foundational studies and the existing bibliography supplied context. Potentially relevant but nonprioritized records are identified as such in the ledger; they are not classified as full-text exclusions. The review does not claim exhaustive model coverage, duplicate independent screening or a formal systematic-review flow.

The accompanying 126695-Revision-Search-Records.zip contains exact query metadata, retrieved identifiers and titles, duplicate matching, screening/prioritization decisions, bibliography-route matching and a data dictionary. Raw retrieval responses and accessible primary-source documents are retained in the local research archive.

2 Sources and executed strategies

PubMed was searched through official NCBI E-utilities. Each query requested up to 10000 identifiers, more than the count for that query, with publication-date sorting. All 6401 query hits were retrieved; overlapping hits represented 5233 distinct PMIDs.

The query translations, warnings and retrieval timestamps are in the accompanying search metadata. Multiple query memberships were retained for each PMID.

Q01: Functional cure and antigen clearance (2219 records)

((("Hepatitis B, Chronic"[Mesh] OR "Hepatitis B virus"[Mesh] OR "hepatitis B"[Title/ Abstract] OR HBV[Title/ Abstract]) AND ("functional cure"[Title/ Abstract] OR "HBsAg loss"[Title/ Abstract] OR "HBsAg seroclearance"[Title/ Abstract] OR "HBsAg clearance"[Title/ Abstract] OR "surface antigen loss"[Title/ Abstract] OR "surface antigen seroclearance"[Title/ Abstract])) AND ("2000/01/01"[Date - Publication] : "2026/09/14"[Date - Publication])

Q02: Investigational curative therapies (398 records)

((("Hepatitis B, Chronic"[Mesh] OR "Hepatitis B virus"[Mesh] OR "hepatitis B"[Title/ Abstract] OR HBV[Title/ Abstract]) AND (bepirovirsen[Title/ Abstract] OR imdusiran[Title/ Abstract] OR elebsiran[Title/ Abstract] OR xalnesiran[Title/ Abstract] OR "JNJ-3989"[Title/ Abstract] OR "ARC-520"[Title/ Abstract] OR bersacapavir[Title/ Abstract] OR vebicorvir[Title/ Abstract] OR selgantolimod[Title/ Abstract] OR "BRII-179"[Title/ Abstract] OR "REP 2139"[Title/ Abstract] OR "REP 2165"[Title/ Abstract] OR ((siRNA[Title/ Abstract] OR "antisense oligonucleotide"[Title/ Abstract] OR "therapeutic vaccine"[Title/ Abstract] OR "capsid assembly modulator"[Title/ Abstract]) AND (trial[Title/ Abstract] OR patients[Title/ Abstract]))) AND ("2000/01/01"[Date - Publication] : "2026/09/14"[Date - Publication])

Q03: Serum biomarkers and transcription (521 records)

((("Hepatitis B, Chronic"[Mesh] OR "Hepatitis B virus"[Mesh] OR "hepatitis B"[Title/ Abstract] OR HBV[Title/ Abstract]) AND (HBcrAg[Title/ Abstract] OR "core-related antigen"[Title/ Abstract] OR "serum HBV RNA"[Title/ Abstract] OR "circulating HBV RNA"[Title/ Abstract] OR "quantitative anti-HBc"[Title/ Abstract] OR "quantitative antibody to hepatitis B core"[Title/ Abstract]) AND (predict*[Title/ Abstract] OR biomarker*[Title/ Abstract] OR diagnos*[Title/ Abstract] OR transcription[Title/ Abstract] OR treatment[Title/ Abstract] OR

genotype*[Title/ Abstract])) AND ("2000/01/01"[Date - Publication] :
"2026/09/14"[Date - Publication])

Q04: Prediction methods for treatment response (180 records)

((("Hepatitis B, Chronic"[Mesh] OR "Hepatitis B virus"[Mesh] OR "hepatitis B"[Title/ Abstract] OR HBV[Title/ Abstract]) AND ("Machine Learning"[Mesh] OR "machine learning"[Title/ Abstract] OR "artificial intelligence"[Title/ Abstract] OR "deep learning"[Title/ Abstract] OR "prediction model"[Title/ Abstract] OR "predictive model"[Title/ Abstract] OR nomogram*[Title/ Abstract]) AND (cure[Title/ Abstract] OR HBsAg[Title/ Abstract] OR "treatment response"[Title/ Abstract] OR interferon[Title/ Abstract])) AND ("2000/01/01"[Date - Publication] : "2026/09/14"[Date - Publication])

Q05: HCC and liver-related risk prediction (515 records)

((("Hepatitis B, Chronic"[Mesh] OR "Hepatitis B virus"[Mesh] OR "hepatitis B"[Title/ Abstract] OR HBV[Title/ Abstract]) AND ("Carcinoma, Hepatocellular"[Mesh] OR "hepatocellular carcinoma"[Title/ Abstract] OR HCC[Title/ Abstract] OR "liver-related"[Title/ Abstract]) AND ("risk score"[Title/ Abstract] OR "risk prediction"[Title/ Abstract] OR "prediction model"[Title/ Abstract] OR "predictive model"[Title/ Abstract] OR PAGE-B[Title/ Abstract] OR REACH-B[Title/ Abstract] OR aMAP[Title/ Abstract] OR PLAN-B[Title/ Abstract])) AND ("2000/01/01"[Date - Publication] :
"2026/09/14"[Date - Publication])

Q06: Cancer and outcomes after antigen clearance (483 records)

((("Hepatitis B, Chronic"[Mesh] OR "Hepatitis B virus"[Mesh] OR "hepatitis B"[Title/ Abstract] OR HBV[Title/ Abstract]) AND (seroclearance[Title/ Abstract] OR "HBsAg loss"[Title/ Abstract] OR "HBsAg clearance"[Title/ Abstract] OR "surface antigen loss"[Title/ Abstract]) AND ("hepatocellular carcinoma"[Title/ Abstract] OR HCC[Title/ Abstract] OR surveillance[Title/ Abstract] OR mortality[Title/ Abstract] OR decompensation[Title/ Abstract])) AND ("2000/01/01"[Date - Publication] :
"2026/09/14"[Date - Publication])

Q07: NA cessation and treatment harm (409 records)

((("Hepatitis B, Chronic"[Mesh] OR "Hepatitis B virus"[Mesh] OR "hepatitis B"[Title/ Abstract] OR HBV[Title/ Abstract]) AND ("nucleos(t)ide"[Title/ Abstract] OR nucleoside[Title/ Abstract] OR nucleotide[Title/ Abstract] OR entecavir[Title/ Abstract] OR tenofovir[Title/ Abstract]) AND (withdrawal[Title/ Abstract] OR cessation[Title/ Abstract] OR discontinuation[Title/ Abstract] OR stopping[Title/ Abstract]) AND (safety[Title/ Abstract] OR flare*[Title/ Abstract] OR decompensation[Title/ Abstract] OR death[Title/ Abstract] OR retreatment[Title/ Abstract] OR randomized[Title/ Abstract])) AND ("2000/01/01"[Date - Publication] : "2026/09/14"[Date - Publication])

Q08: Guidelines, consensus and evidence syntheses (1551 records)

((("Hepatitis B, Chronic"[Mesh] OR "Hepatitis B virus"[Mesh] OR "hepatitis B"[Title/ Abstract] OR HBV[Title/ Abstract]) AND (Guideline[Publication Type] OR Practice Guideline[Publication Type] OR "Meta-Analysis"[Publication Type] OR "systematic review"[Title/ Abstract] OR guideline*[Title] OR consensus[Title]) AND (cure[Title/ Abstract] OR HBsAg[Title/ Abstract] OR biomarker*[Title/ Abstract] OR surveillance[Title/ Abstract] OR treatment[Title/ Abstract] OR "risk prediction"[Title/ Abstract])) AND ("2000/01/01"[Date - Publication] : "2026/09/14"[Date - Publication])

Q09: Genotype and regional transportability (96 records)

((("Hepatitis B, Chronic"[Mesh] OR "Hepatitis B virus"[Mesh] OR "hepatitis B"[Title/ Abstract] OR HBV[Title/ Abstract]) AND ("genotype D"[Title/ Abstract] OR "genotype E"[Title/ Abstract] OR Africa*[Title/ Abstract] OR Egypt*[Title/ Abstract]) AND (cure[Title/ Abstract] OR "HBsAg loss"[Title/ Abstract] OR seroclearance[Title/ Abstract] OR HBcrAg[Title/ Abstract] OR "risk score"[Title/ Abstract] OR "prediction model"[Title/ Abstract] OR "machine learning"[Title/ Abstract])) AND ("2000/01/01"[Date - Publication] : "2026/09/14"[Date - Publication])

Q10: HCC surveillance society guidance (29 records)

((("hepatocellular carcinoma"[Title] OR HCC[Title]) AND (AASLD[Title] OR EASL[Title] OR APASL[Title]) AND (guideline*[Title] OR guidance[Title])) AND ("2000/01/01"[Date - Publication] : "2026/09/14"[Date - Publication]))

Cochrane Database of Systematic Reviews

Platform: Cochrane Library. Search field: Title, Abstract, Keyword. Executed query: ("hepatitis B" OR HBV) AND ("functional cure" OR HBsAg OR seroclearance). No interface filters were applied. Eight review records were read and manually recorded from their visible primary pages. Five exact DOI matches overlapped PubMed; three records were additional. The 2730 CENTRAL trial results displayed by the same interface were not retrieved or screened and are outside the record-flow totals.

Scopus retrieval attempt

The advanced document search returned 4281 results. The interface generated an all-record CSV export, but the **export file could not be downloaded**. No Scopus record export was obtained and no Scopus-only records were screened. The result count is reported as a source-access audit, not included among retrieved or screened records.

TITLE-ABS-KEY ("hepatitis B" OR HBV) AND TITLE-ABS-KEY ("functional cure" OR "HBsAg loss" OR "HBsAg seroclearance" OR "HBsAg clearance" OR HBcrAg OR bepirovirsen OR imdusiran OR elebsiran OR xalnesiran OR "machine learning" OR PAGE-B OR REACH-B OR aMAP OR PLAN-B OR (("hepatocellular carcinoma" OR HCC) AND ("risk score" OR "risk prediction" OR "prediction model"))) AND PUBYEAR > 1999 AND PUBYEAR < 2027

Embase was inaccessible through the available account. Web of Science and a separate MEDLINE platform were not searched. These limits narrow database coverage and may particularly affect conference, regional and non-PubMed evidence. Earlier focused reference checks and exploratory terminology queries were not pooled into the full-search retrieval counts.

3 Record accounting and appraisal

The 6401 PubMed query hits contained 1168 repeated PMID occurrences, leaving 5233 distinct PubMed records. Eight Cochrane review records contributed five cross-source duplicates and three additional records. All 5236 distinct database titles were considered. The title/abstract ledger records 134 PubMed abstracts actually appraised during this broader search; 8 Cochrane abstracts were appraised, with cross-source overlap retained explicitly. Remaining records have title/metadata dispositions rather than inferred abstract or full-text decisions.

Bibliography checking separately considered the 44 references in the preceding revision draft, of which 40 already occurred in the database set and 4 were additional reference-route records. These references were checked as identified source records rather than counted as newly screened database hits. The revised bibliography contains 58 references. Citation selection is a narrative decision and is not an estimate of the total number of eligible studies.

Deduplication used PMID first and DOI/title as identity checks. Distinct PubMed records sharing a DOI were retained when they were separate letters, replies or other reports. Normalized title matches were not merged automatically because corrections, updates and separate reports can share titles. The duplicate ledger preserves the five Cochrane-to-PubMed matches. Studies and their secondary reports were not treated as independent randomized comparisons.

Appraisal examined study design, comparators, selected populations, outcome definitions, denominators, treatment background, follow-up and adverse-event windows. Model appraisal examined predictor availability at the decision time, outcome events, missing data, development and validation, discrimination, calibration and clinical thresholds. No formal risk-of-bias instrument, certainty score, independent duplicate screening, re-analysis or quantitative pooling was undertaken. Primary-access limitations, including unextracted PLAN-B-CURE validation estimates and some assay thresholds, remain explicit in the tables.

4 AI-assisted work and evidence checks

The saved ledger states the stage actually reached for each record. ChatGPT (OpenAI; ChatGPT 5.6) assisted with literature searching, language editing, grammatical correction, and figure design. All AI-assisted content was reviewed and verified by the author, who takes full responsibility for the integrity, accuracy, and originality of the final work.

The update adds negative combination results and drug-induced liver injury evidence, separates baseline PegIFN prognosis from comparative regimen allocation, incorporates direct post-HBsAg-loss model validation, and distinguishes prospective model-validation protocols from completed results. Society recommendations are attributed individually where they differ. These additions refine the review without converting it into a systematic review.

5 Reference verification register

Numbers match the revised manuscript. Original reference numbers are retained for comparison with the submitted version; additions are marked new. All PMID/DOI identities were checked against retrieved bibliographic records. Source existence was checked separately from the support it provides for a numerical or clinical statement. Journal publication years are used where final issue information is available.

1 (original 1). Global, regional, and national burden of chronic hepatitis B, 1990-2021, and projections to 2030: An urgent call for action to achieve hepatitis B elimination goals by 2030

Hum Vaccin Immunother 2026; 22: 2641857. PMID: 41804590. DOI: 10.1080/21645515.2026.2641857.

2 (original 2). Declining but persistent hepatocellular cancer risk beyond 10 years of entecavir or tenofovir in chronic hepatitis B: Results from the PAGE-B cohort

J Hepatol 2026; Epub ahead of print. PMID: 42409322. DOI: 10.1016/j.jhep.2026.06.038.

3 (original 3). Long-term HBsAg clearance, relapse, and safety following tenofovir or entecavir discontinuation in non-cirrhotic, HBeAg-negative chronic hepatitis

Sci Rep 2026; 16: 10404. PMID: 41735396. DOI: 10.1038/s41598-026-40972-y.

4 (original 4). Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference

J Hepatol 2023; 79: 1254-1269. PMID: 37377088. DOI: 10.1016/j.jhep.2023.06.002.

5 (original 5). Hepatitis B Surface Antigen Loss and Improved Clinical Outcomes in US Individuals With Chronic Hepatitis B Virus Infection

J Viral Hepat 2026; 33: e70184. PMID: 42141794. DOI: 10.1111/jvh.70184.

6 (original 6). Emerging therapies for HBsAg seroclearance: spotlight on novel combination strategies

Hepatol Int 2025; 19: 704-719. PMID: 40495020. DOI: 10.1007/s12072-025-10828-0.

7 (original 7). RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg

Sci Transl Med 2017; 9: eaan0241. PMID: 28954926. DOI:

10.1126/scitranslmed.aan0241.

8 (original 8). The small interfering RNA imdusiran as single and multiple doses in healthy, randomised individuals and non-randomised individuals with chronic hepatitis B (AB-729-001): a phase 1a/b trial

Lancet Gastroenterol Hepatol 2026; 11: 579-601. PMID: 42173110. DOI:

10.1016/S2468-1253(26)00058-0.

9 (original 9). Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989

Gut 2025; 74: 440-450. PMID: 39266050. DOI: 10.1136/gutjnl-2024-333026.

10 (original 10). Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B

N Engl J Med 2024; 391: 2098-2109. PMID: 39774313. DOI: 10.1056/NEJMoa2405485.

11 (original 11). Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial

Lancet Gastroenterol Hepatol 2023; 8: 790-802. PMID: 37442152. DOI: 10.1016/S2468-1253(23)00148-6.

12 (original 12). VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study

Lancet Gastroenterol Hepatol 2024; 9: 1121-1132. PMID: 39389081. DOI: 10.1016/S2468-1253(24)00237-1.

13 (new). Elebsiran and PEG-IFN α for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial

Nat Med 2026; 32: 151-159. PMID: 41203919. DOI: 10.1038/s41591-025-04049-z.

14 (original 13). Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection

J Hepatol 2022; 77: 642-652. PMID: 35460726. DOI: 10.1016/j.jhep.2022.04.005.

15 (original 14). The Impact of Hepatitis B Surface Antigen Reduction via Small Interfering RNA Treatment on Natural and Vaccine (BRII-179)-Induced Hepatitis B Virus-Specific Humoral and Cellular Immune Responses

Gastroenterology 2025; 169: 136-149. PMID: 40043858. DOI: 10.1053/j.gastro.2025.02.016.

16 (original 15). Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection

N Engl J Med 2022; 387: 1957-1968. PMID: 36346079. DOI: 10.1056/NEJMoa2210027.

17 (original 16). Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection

N Engl J Med 2026; 394: 2395-2406. PMID: 42206582. DOI: 10.1056/NEJMoa2515131.

18 (original 17). Bepirovirsen induces innate immune activation in the liver potentially through TLR8 signaling

JHEP Rep 2026; 8: 101923. PMID: 42264034. DOI: 10.1016/j.jhepr.2026.101923.

19 (original 18). Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B

J Hepatol 2025; 82: 222-234. PMID: 39214467. DOI: 10.1016/j.jhep.2024.08.010.

20 (original 19). Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression

J Hepatol 2023; 78: 513-523. PMID: 38133554. DOI: 10.1016/j.jhep.2022.09.027.

21 (original 20). A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B

J Hepatol 2023; 78: 926-936. PMID: 37062574. DOI: 10.1016/j.jhep.2022.12.018.

22 (new). No Impact of Low-Dose Nivolumab Addition to JNJ-73763989 on Hepatitis B Surface Antigen Declines in Chronic Hepatitis B: The OCTOPUS-1 Study

Clin Gastroenterol Hepatol 2026; Epub ahead of print. PMID: 42320551. DOI: 10.1016/j.cgh.2026.06.018.

23 (new). Peginterferon alpha-2a add-on to siRNA JNJ-73763989 in untreated patients with HBeAg-positive chronic hepatitis B virus (HBV) infection: the phase 2 REEF-IT study

Gut 2026; 75: 1043-1054. PMID: 41193172. DOI: 10.1136/gutjnl-2025-336592.

24 (new). ALG-020572, an Antisense Oligonucleotide for the Treatment of Chronic Hepatitis B Virus Infection Discontinued for Drug-Induced Liver Injury

J Viral Hepat 2026; 33: e70224. PMID: 42638560. DOI: 10.1111/jvh.70224.

25 (new). Novel HBV Biomarkers-Guided NAs Withdrawal Strategy Promotes HBsAg Clearance in Asian CHB Patients: A Randomized Controlled Trial

Clin Gastroenterol Hepatol 2026; 24: 1611-1620. PMID: 40953786. DOI: 10.1016/j.cgh.2025.09.009.

26 (original 21). High accuracy model for HBsAg loss based on longitudinal trajectories of serum qHBsAg throughout long-term antiviral therapy

Gut 2024; 73: 1725-1736. PMID: 38902029. DOI: 10.1136/gutjnl-2024-332182.

27 (original 22). Large-scale profile study on hepatitis B surface antigen levels in chronic hepatitis B: implications for drug development targeting functional cure

Gut 2026; 75: 119-130. PMID: 40764062. DOI: 10.1136/gutjnl-2025-335219.

28 (original 23). On-treatment viral factors affect subsequent hepatitis B surface antigen seroclearance in patients treated with nucleos(t)ide analogs for > 10 years

J Gastroenterol 2026; 61: 990-1002. PMID: 42012634. DOI: 10.1007/s00535-026-02415-3.

29 (original 24). Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants

Clin Gastroenterol Hepatol 2021; 19: 46-60.e8. PMID: 32360825. DOI: 10.1016/j.cgh.2020.04.045.

30 (original 25). Quantification of circulating HBV RNA expressed from intrahepatic cccDNA in untreated and NUC treated patients with chronic hepatitis B

Gut 2024; 73: 659-667. PMID: 37879886. DOI: 10.1136/gutjnl-2023-330644.

31 (original 26). Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues

Gut 2016; 65: 313-20. PMID: 25586058. DOI: 10.1136/gutjnl-2014-308546.

- 32 (original 27). Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)
Clin Gastroenterol Hepatol 2022; 20: e784-e793. PMID: 33309804. DOI: 10.1016/j.cgh.2020.12.005.
- 33 (original 28). Getting to HBV cure-Will new biomarkers help?
Hepatology 2026; 84: 582-600. PMID: 40168396. DOI: 10.1097/HEP.0000000000001334.
- 34 (new). Adding HBV RNA and HBcrAg to HBsAg Improves Prediction of HBsAg Seroclearance in NAs-Suppressed CHB Treated With Peg-IFN- α
Liver Int 2026; 46: e70741. PMID: 42266011. DOI: 10.1111/liv.70741.
- 35 (new). HBcrAg and cirB-RNA Do Not Predict Clinical and Virological Outcomes in Patients With HBeAg-Negative Chronic Infection
Liver Int 2025; 45: e70072. PMID: 40257408. DOI: 10.1111/liv.70072.
- 36 (original 29). Machine learning prediction of rapid HBsAg seroclearance at week 24 in inactive carriers treated with pegylated interferon
Hepatology 2025; 19: 1331-1346. PMID: 41249755. DOI: 10.1007/s12072-025-10936-x.
- 37 (new). Development and Validation of a Predictive Model for HBsAg Seroclearance After Peg-IFN-Based Therapy: A Multicentre Study
Drug Des Devel Ther 2025; 19: 9973-9982. PMID: 41229921. DOI: 10.2147/DDDT.S545700.
- 38 (new). Machine learning prediction of functional cure to pegylated interferon-alpha therapy in two HBV populations: Advantaged populations and HBeAg-negative patients
Virulence 2026; 17: 2629088. PMID: 41656920. DOI: 10.1080/21505594.2026.2629088.
- 39 (original 30). A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B
J Hepatol 2025; 82: 235-244. PMID: 39218223. DOI: 10.1016/j.jhep.2024.08.016.

40 (original 31). Artificial Intelligence in hepatology: A position paper by the Italian Association for the Study of the Liver

Dig Liver Dis 2026; 58: 747-758. PMID: 41876274. DOI: 10.1016/j.dld.2026.03.005.

41 (original 32). TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods

BMJ 2024; 385: e078378. PMID: 38626948. DOI: 10.1136/bmj-2023-078378.

42 (new). Nucleos(t)ide analogue therapy combined with pegylated interferon α -2b guided by the GOLDEN prediction model for functional cure of chronic hepatitis B: study protocol (GIFT project)

BMJ Open 2026; 16: e114224. PMID: 42608047. DOI: 10.1136/bmjopen-2025-114224.

43 (original 33). Long-Term Incidence of Hepatocellular Carcinoma After Hepatitis B Surface Antigen Seroclearance

Gastroenterology 2026; Epub ahead of print. PMID: 42442512. DOI: 10.1053/j.gastro.2026.06.022.

44 (original 34). Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score

Lancet Oncol 2011; 12: 568-74. PMID: 21497551. DOI: 10.1016/S1470-2045(11)70077-8.

45 (original 35). PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy

J Hepatol 2016; 64: 800-6. PMID: 26678008. DOI: 10.1016/j.jhep.2015.11.035.

46 (original 36). aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis

J Hepatol 2020; 73: 1368-1378. PMID: 32707225. DOI: 10.1016/j.jhep.2020.07.025.

47 (new). Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance

Clin Transl Gastroenterol 2021; 12: e00290. PMID: 33433118. DOI: 10.14309/ctg.0000000000000290.

48 (new). CAMP-B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance

Aliment Pharmacol Ther 2024; 59: 1223-1235. PMID: 38425096. DOI: 10.1111/apt.17933.

49 (original 37). An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B

J Hepatol 2022; 76: 311-318. PMID: 34606915. DOI: 10.1016/j.jhep.2021.09.025.

50 (new). Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis

Diagnostics (Basel) 2023; 13: 3. PMID: 36611295. DOI: 10.3390/diagnostics13010003.

51 (new). AASLD/IDSA Practice Guideline on treatment of chronic hepatitis B

Hepatology 2026; 83: 974-997. PMID: 41186418. DOI: 10.1097/HEP.0000000000001549.

52 (new). EASL Clinical Practice Guidelines on the management of hepatitis B virus infection

J Hepatol 2025; 83: 502-583. PMID: 40348683. DOI: 10.1016/j.jhep.2025.03.018.

53 (new). EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma

J Hepatol 2025; 82: 315-374. PMID: 39690085. DOI: 10.1016/j.jhep.2024.08.028.

54 (new). APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update

Hepatol Int 2026; 20: 911-942. PMID: 42365189. DOI: 10.1007/s12072-026-11108-1.

55 (new). AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma

Hepatology 2023; 78: 1922-1965. PMID: 37199193. DOI: 10.1097/HEP.0000000000000466.

56 (original 38). Genetic Epidemiology of Hepatitis B Virus in Africa: A Review
Gastro Hep Adv 2026; 5: 100968. PMID: 42181859. DOI: 10.1016/j.gastha.2026.100968.

57 (new). Mac-2 binding protein glycosylation isomer (M2BPGi) to evaluate liver
fibrosis and cancer in HBV-infected patients in West Africa
J Glob Health 2022; 12: 04076. PMID: 36370422. DOI: 10.7189/jogh.12.04076.

58 (original 39). Between the hype and harm: does artificial intelligence in health
offer solace or further exclusion for marginalised populations in Sub-Saharan Africa?
A scoping review
Glob Health Action 2026; 19: 2710547. PMID: 42544917. DOI:
10.1080/16549716.2026.2710547.